Developer docs
API playgroundTry for free, no card

Search company profiles

Niagen Bioscience

Full company profile

uuid0000xmh

Namestring
Niagen Bioscience
Legal namestring
ChromaDex, Inc.
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Niagen Bioscience (NASDAQ: NAGE), founded in 1999 and headquartered in Los Angeles, is a vertically integrated NAD+ science company built around its patented nicotinamide riboside chloride ingredient (Niagen). The company holds what it describes as the only U.S. Pharmacopeia monograph among NAD+ precursors, supported by FDA NDI notifications, GRAS status, Health Canada, Australian TGA, and EFSA approvals, and a portfolio of 60+ patents including US 12,558,367 covering IV and injectable NR formulations through approximately 2044. The business spans consumer oral supplements (Tru Niagen and the November 2025 Tru Niagen Beauty launch), pharmaceutical-grade IV and injectable therapies (Niagen Plus, distributed through 1,200+ clinical partners and a newly launched May 2026 telehealth platform dispensing at-home injection kits), topical skincare (March 2026's Niagen NanoCloud waterless sachets), and B2B ingredient licensing to manufacturers and brand partners.

The company operates four reinforcing go-to-market motions: DTC e-commerce with subscription and HSA/FSA eligibility (via Truemed), a clinical channel of 1,200+ healthcare, wellness, and longevity clinics plus 80+ OneSpaWorld cruise ship medi-spas served by dual 503B compounding partners (Wells Pharmacy of Houston and Olympia Pharmaceuticals), clinician-directed telehealth for prescription-only injectables, and global B2B licensing supported by the Niagen Research Program's 300+ research collaborations across 34 countries and 500+ publications. FY2025 net sales reached $129.4M (up 30% YoY) with net income of $17.4M, adjusted EBITDA of $20.4M, and 64.3% gross margin; the company exited FY2025 with $64.8M cash and zero debt, and guided 10-15% growth for 2026. The divestiture of ChromaDex Reference Standards to LGC in February 2026 reflects a deliberate narrowing of scope toward NAD+ therapeutics and longevity.

Short descriptiontext

Niagen Bioscience (NASDAQ: NAGE) is a vertically integrated NAD+ science company that develops, patents, and commercializes nicotinamide riboside (Niagen) via consumer supplements, clinical IV and injectable therapies, and B2B ingredient licensing across more than 1,200 clinics and a new telehealth channel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NAD+ precursor supplements, nicotinamide riboside ingredients, cellular health supplements, longevity science products, pharmaceutical-grade NAD+ therapy
Industry2 codes
PRIMARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
NAD+ Dietary Supplements
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Consumer Supplement Sales (Tru Niagen)
TypeSubscription Recurring
Description

Direct-to-consumer e-commerce sales of Tru Niagen oral NAD+ supplements through truniagen.com. The brand is positioned as America's trusted NAD-boosting supplement with clinically proven daily support. Sales driven by subscription model with flexible serving options and superior bioavailability.

longevity.technology
2Clinical/Pharmaceutical Therapy (Niagen Plus)
TypeTransaction Fee
Description

Revenue from pharmaceutical-grade Niagen IV and injectable therapies distributed through 1,200+ healthcare clinics, telehealth platform, and cruise ship medi-spas. Products include prescription-only subcutaneous injection kits and intravenous formulations dispensed through licensed 503A/503B compounding pharmacies.

businesswire.com
3Skincare Products (Niagen NanoCloud)
TypeOne Time License
Description

Sales of Niagen NanoCloud topical skincare sachets launched March 2026 at $59 per 30-sachet unit. Waterless powder format extends NAD+ science into cosmetics market, generating consumer insights for future topical product development.

pharmiweb.com
4B2B Ingredient Licensing
TypeLicensing Royalties
Description

Revenue from licensing Niagen ingredient to manufacturers, healthcare innovators, and brands for incorporation into their products. Company collaborates with global partners to push boundaries of NAD+ science through research partnerships and ingredient supply agreements.

stocktitan.net
5Niagen Beauty Supplement (Tru Niagen Beauty)
TypeSubscription Recurring
Description

Sales of Tru Niagen Beauty, launched November 2025, combining NAD+ support with skin and hair ingredients including astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E. Targets cellular health and beauty from within.

nutraingredients.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Marketing or Sales, Personnel, Supply Chain
Pricing details2 tiers
1Niagen NanoCloud topical skincare sachets
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$59 per unit of 30 sachets (water-activated powder format)

pharmiweb.com
2Niagen Plus telehealth platform injection kits
ModelOtherBilling cadencePay-as-you-go
Notes

Prescription-only pharmaceutical-grade Niagen via at-home subcutaneous injection kits dispensed through licensed 503A pharmacies; dosing at 50mg or 100mg; specific pricing not publicly disclosed

simplywall.st
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Tru Niagen®
Description

Premium food-grade oral NAD+ supplement brand for daily cellular vitality support.

niagenbioscience.com
+2 more records
Core offering1 text field

Niagen Bioscience develops, manufactures, and commercializes its patented Niagen (nicotinamide riboside chloride) ingredient across consumer dietary supplements (Tru Niagen, Tru Niagen Beauty), pharmaceutical-grade clinical therapies (Niagen Plus IV and injectables), topical skincare (Niagen NanoCloud), and B2B ingredient licensing to manufacturers. The company operates a direct-to-consumer e-commerce platform, a clinician-directed telehealth platform for prescription at-home injection kits, and a network of over 1,200 clinics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Increases NAD+ levels by up to 150%
+4 more records
Product overview1 text field

Niagen Bioscience operates two primary brand lines powered by its patented Niagen nicotinamide riboside ingredient: Tru Niagen (consumer dietary supplements for daily NAD+ boosting) and Niagen Plus (pharmaceutical-grade IV and injectable NAD+ therapies through healthcare providers). Tru Niagen encompasses oral supplements including the original Tru Niagen, Tru Niagen Beauty (NAD-focused skincare supplement), and related products. Niagen Plus includes clinical IV therapies at over 1,200 clinics plus the new telehealth-enabled at-home injection platform. The company also recently launched Niagen NanoCloud through its Skincare Innovation Lab—a topical skincare entry using waterless sachet technology. The company sponsors the Niagen Research Program (formerly CERP) supporting external NAD+ research globally. Revenue streams include direct-to-consumer e-commerce (Tru Niagen), B2B ingredient sales, and clinical/ telehealth channels (Niagen Plus).

Product and service5 records
1Tru Niagen
CategoryConsumer Dietary Supplement
Description

Premium food-grade oral NAD+ supplement containing patented nicotinamide riboside (Niagen), clinically proven to boost NAD+ levels by up to 150% and support cellular energy, repair, and healthy aging. Available in various serving sizes via subscription e-commerce at truniagen.com. Targeted at health-conscious adult consumers.

2Niagen Plus
CategoryPharmaceutical-Grade Clinical Therapy
Description

Pharmaceutical-grade NAD+ enhancement therapy delivered through healthcare providers and a new telehealth platform. Includes Niagen IV (intravenous) and injectable formulations available at over 1,200 clinics nationwide plus at-home subcutaneous injection kits dispensed by licensed 503A/503B pharmacies. Targeted at medical patients and clinical operators.

3Tru Niagen Beauty
CategoryBeauty Dietary Supplement
Description

NAD-focused beauty supplement combining Niagen with astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E to support skin elasticity, hair strength, and nail health from within. Sold via subscription through truniagen.com. Targeted at premium beauty and longevity consumers.

4Niagen NanoCloud
CategoryTopical Skincare
Description

Waterless topical skincare product in sachet format delivering patented Niagen nicotinamide riboside. Protects NR from degradation until point of use, solving instability challenges common in NAD+ skincare formulations. Dermatologist-tested. Targeted at premium anti-aging skincare consumers.

5Niagen (Nicotinamide Riboside Chloride) Ingredient
CategoryB2B Ingredient Supply
Description

B2B patented nicotinamide riboside chloride (NRCl) ingredient licensed to manufacturers, healthcare innovators, and brand partners for incorporation into consumer health, nutraceutical, and pharmaceutical products. FDA NDI notified (2015, 2018), GRAS status (2016), USP monograph published. Targeted at consumer health manufacturers and brand partners globally.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierStrategicTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-05-04
Description

Partnership with Taiki, a leading Korean manufacturer specializing in innovative delivery formats, for production of Niagen NanoCloud sachets. Waterless powder format developed in partnership protects Niagen until the moment of use, solving stability challenge that limits traditional NAD+ skincare products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-28
Description

Partnership with Olympia Pharmaceuticals, a U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen for Niagen Plus intravenous and injectable products. Addition diversifies Niagen Bioscience's 503B compounding network beyond existing partner Wells Pharma of Houston, expanding supply chain capabilities to support growth across clinic footprint nationwide. Collaboration meets growing demand for Niagen IV and injections in healthy aging and longevity market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-31
Description

Partnership to offer pharmaceutical-grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships, marking the company's first cruise ship clinic partnership. Collaboration extends Niagen's clinical network to new premium distribution point targeting on-vacation consumers seeking wellness experiences, with deployment aligned to ship-specific operations and regulatory requirements. Rollout expected to meaningfully expand OneSpaWorld's fleet footprint while providing scalable pathway for Niagen Plus to reach new consumers.

Strategic tierMinorTypeOthersAnnounced on2026-02-24
Description

Sale of ChromaDex Reference Standards business to LGC in all-cash transaction. Deal enables Niagen Bioscience to exit non-core activities and focus on NAD+ science. LGC Standards, a division of LGC Group, acquired analytical reference standards and services business to expand North American commercial reach and enhance reference materials portfolio for pharmaceutical, laboratory, and food production customers.

Strategic tierMinorTypeOthersAnnounced on2026-02-24
Description

LGC Limited acquired ChromaDex Reference Standards from Niagen Bioscience in February 2026, strengthening LGC's ability to serve pharmaceutical customers, testing laboratories, and food producers while expanding North American commercial reach.

6University of Copenhagen
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-09
Description

Premiere sponsor of inaugural 'NAD for Health: Opportunities & Challenges' scientific conference hosted by University of Copenhagen (March 23-25, 2026). Conference focuses on NAD metabolism research, aging biology, and translational frameworks, bringing together researchers, clinicians, and industry partners. Dr. Jonas Treebak and Dr. Vilhelm Bohr organizing the event, with Dr. Bohr serving on Niagen Bioscience's Scientific Advisory Board.

businesswire.com
Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-29
Description

Partnership enabling qualified customers to purchase Tru Niagen using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds. Truemed provides a Letter of Medical Necessity for eligible buyers, expanding accessibility of the NAD+ supplement to consumers with pre-tax healthcare accounts.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-22
Description

Acquisition of comprehensive patent portfolio covering nicotinamide riboside (NR) from Queen's University Belfast. Transaction consolidates Niagen Bioscience's leadership position in NAD+ precursor intellectual property, covering manufacturing, composition, and use rights globally. Grant includes various NR salt forms and derivatives, making company sole owner of critical IP in NAD+ industry.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research collaboration through Niagen Research Program with investigators from Mayo Clinic among 300+ global research collaborations supporting NAD+ science. Mayo Clinic researchers participate in investigator-initiated studies using Niagen materials provided through Material Transfer Agreements.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research collaboration through Niagen Research Program with investigators from National Institutes of Health among 300+ global research agreements. NIH researchers participate in investigator-initiated and third-party funded studies advancing NAD+ biology understanding.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research collaboration through Niagen Research Program with investigators from Harvard University. Harvard researchers contribute to peer-reviewed publications on NR and NAD+ biology through investigator-initiated studies.

12Cambridge University
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research collaboration through Niagen Research Program with investigators from Cambridge University among leading research institutions supporting NAD+ science and clinical studies.

nasdaq.com
13MIT
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research collaboration through Niagen Research Program with investigators from MIT contributing to NAD+ precursor research and clinical studies.

nasdaq.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Designs for Health is a practitioner-grade supplement company with a clinical channel model very similar to Niagen's 1,200+ clinic distribution network. Comparable on professional channel distribution, premium quality positioning, and cellular health product focus.

TypeEmerging player
Description

Neurohacker Collective sells Qualia line supplements targeting longevity, cognition, and cellular health. It overlaps on longevity positioning and the science-led premium supplement category, though its core focus is broader nootropic/longevity rather than NAD+ specifically.

TypeDirect peer
Description

Momentous is a premium longevity and human performance supplement brand with scientific advisory ties (e.g., Dr. Andrew Huberman) and an emphasis on cellular health, mitochondrial function, and NAD+ support — a peer in the premium longevity DTC category.

TypeDirect peer
Description

Elysium Health sells Basis, a direct NAD+ precursor supplement combining nicotinamide riboside with pterostilbene, targeting the same cellular aging and longevity use cases as Tru Niagen. It is the most direct head-to-head competitor in the consumer NAD+ category.

TypeDirect peer
Description

Pure Encapsulations is a practitioner-channel premium supplement brand owned by Nestlé Health Science. It serves healthcare practitioners with hypoallergenic, science-backed formulations — comparable to Niagen's clinical channel strategy and quality positioning.

TypeEmerging player
Description

Restore Hyper Wellness is a national franchise of wellness clinics offering IV therapies including NAD+ and has conducted research on Niagen IV tolerability. Comparable as a clinical channel partner and competitor for IV-based NAD+ delivery.

7Codeage
TypeEmerging player
Description

Codeage is a DTC longevity supplement brand with NAD+, NMN, and cellular aging products targeting the same health-conscious consumer. It is a smaller emerging competitor in the direct NAD+ precursor space.

TypeDirect peer
Description

Life Extension is a long-established direct-to-consumer longevity supplement brand with a broad catalog including NAD+ and cellular health products. It targets the same health-conscious, anti-aging consumer demographic and competes directly on subscription DTC channels.

TypeDirect peer
Description

Thorne is a premium, practitioner-grade supplement brand with a strong scientific positioning, NSF Certified for Sport, and a similar longevity/cellular health focus. Comparable on premium positioning, clinical channel distribution, and science-led brand-building to Niagen's Tru Niagen line.

TypeEmerging player
Description

Jinfiniti offers NAD+ testing and measurement services for consumers and researchers, addressing the same NAD+ science ecosystem. It is adjacent rather than directly competitive but operates in the same NAD+ biology category and serves overlapping consumer/research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Niagen Bioscience

NAD+ Dietary Supplementsniagenbioscience.com

Niagen Bioscience (NASDAQ: NAGE) is a vertically integrated NAD+ science company that develops, patents, and commercializes nicotinamide riboside (Niagen) via consumer supplements, clinical IV and injectable therapies, and B2B ingredient licensing across more than 1,200 clinics and a new telehealth channel.

What Niagen Bioscience does

Niagen Bioscience (NASDAQ: NAGE), founded in 1999 and headquartered in Los Angeles, is a vertically integrated NAD+ science company built around its patented nicotinamide riboside chloride ingredient (Niagen). The company holds what it describes as the only U.S. Pharmacopeia monograph among NAD+ precursors, supported by FDA NDI notifications, GRAS status, Health Canada, Australian TGA, and EFSA approvals, and a portfolio of 60+ patents including US 12,558,367 covering IV and injectable NR formulations through approximately 2044. The business spans consumer oral supplements (Tru Niagen and the November 2025 Tru Niagen Beauty launch), pharmaceutical-grade IV and injectable therapies (Niagen Plus, distributed through 1,200+ clinical partners and a newly launched May 2026 telehealth platform dispensing at-home injection kits), topical skincare (March 2026's Niagen NanoCloud waterless sachets), and B2B ingredient licensing to manufacturers and brand partners.

The company operates four reinforcing go-to-market motions: DTC e-commerce with subscription and HSA/FSA eligibility (via Truemed), a clinical channel of 1,200+ healthcare, wellness, and longevity clinics plus 80+ OneSpaWorld cruise ship medi-spas served by dual 503B compounding partners (Wells Pharmacy of Houston and Olympia Pharmaceuticals), clinician-directed telehealth for prescription-only injectables, and global B2B licensing supported by the Niagen Research Program's 300+ research collaborations across 34 countries and 500+ publications. FY2025 net sales reached $129.4M (up 30% YoY) with net income of $17.4M, adjusted EBITDA of $20.4M, and 64.3% gross margin; the company exited FY2025 with $64.8M cash and zero debt, and guided 10-15% growth for 2026. The divestiture of ChromaDex Reference Standards to LGC in February 2026 reflects a deliberate narrowing of scope toward NAD+ therapeutics and longevity.

Niagen Bioscience firmographics

Firmographics
Name
Niagen Bioscience
Legal name
ChromaDex, Inc.
Website
https://niagenbioscience.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
Niagen Bioscience (NASDAQ: NAGE) is a vertically integrated NAD+ science company that develops, patents, and commercializes nicotinamide riboside (Niagen) via consumer supplements, clinical IV and injectable therapies, and B2B ingredient licensing across more than 1,200 clinics and a new telehealth channel.
Ownership category
akta.pro rank

Niagen Bioscience industry classification

Industry
Product category
NAD+ Dietary Supplements
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)

Keywords

  • NAD+ precursor supplements
  • Nicotinamide riboside ingredients
  • Cellular health supplements
  • Longevity science products
  • Pharmaceutical-grade NAD+ therapy

Where Niagen Bioscience is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Niagen Bioscience business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Marketing or Sales, Personnel, Supply Chain

Revenue model

  1. Consumer Supplement Sales (Tru Niagen): Direct-to-consumer e-commerce sales of Tru Niagen oral NAD+ supplements through truniagen.com. The brand is positioned as America's trusted NAD-boosting supplement with clinically proven daily support. Sales driven by subscription model with flexible serving options and superior bioavailability.
  2. Clinical/Pharmaceutical Therapy (Niagen Plus): Revenue from pharmaceutical-grade Niagen IV and injectable therapies distributed through 1,200+ healthcare clinics, telehealth platform, and cruise ship medi-spas. Products include prescription-only subcutaneous injection kits and intravenous formulations dispensed through licensed 503A/503B compounding pharmacies.
  3. Skincare Products (Niagen NanoCloud): Sales of Niagen NanoCloud topical skincare sachets launched March 2026 at $59 per 30-sachet unit. Waterless powder format extends NAD+ science into cosmetics market, generating consumer insights for future topical product development.
  4. B2B Ingredient Licensing: Revenue from licensing Niagen ingredient to manufacturers, healthcare innovators, and brands for incorporation into their products. Company collaborates with global partners to push boundaries of NAD+ science through research partnerships and ingredient supply agreements.
  5. Niagen Beauty Supplement (Tru Niagen Beauty): Sales of Tru Niagen Beauty, launched November 2025, combining NAD+ support with skin and hair ingredients including astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E. Targets cellular health and beauty from within.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goNiagen NanoCloud topical skincare sachets
OtherPay-as-you-goNiagen Plus telehealth platform injection kits

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Niagen Bioscience product offering

Product offering

Core offering

Niagen Bioscience develops, manufactures, and commercializes its patented Niagen (nicotinamide riboside chloride) ingredient across consumer dietary supplements (Tru Niagen, Tru Niagen Beauty), pharmaceutical-grade clinical therapies (Niagen Plus IV and injectables), topical skincare (Niagen NanoCloud), and B2B ingredient licensing to manufacturers. The company operates a direct-to-consumer e-commerce platform, a clinician-directed telehealth platform for prescription at-home injection kits, and a network of over 1,200 clinics.

Product overview

Niagen Bioscience operates two primary brand lines powered by its patented Niagen nicotinamide riboside ingredient: Tru Niagen (consumer dietary supplements for daily NAD+ boosting) and Niagen Plus (pharmaceutical-grade IV and injectable NAD+ therapies through healthcare providers). Tru Niagen encompasses oral supplements including the original Tru Niagen, Tru Niagen Beauty (NAD-focused skincare supplement), and related products. Niagen Plus includes clinical IV therapies at over 1,200 clinics plus the new telehealth-enabled at-home injection platform. The company also recently launched Niagen NanoCloud through its Skincare Innovation Lab—a topical skincare entry using waterless sachet technology. The company sponsors the Niagen Research Program (formerly CERP) supporting external NAD+ research globally. Revenue streams include direct-to-consumer e-commerce (Tru Niagen), B2B ingredient sales, and clinical/ telehealth channels (Niagen Plus).

Differentiator

Problem solved

Functional benefit

Brands

  • Tru Niagen®: Premium food-grade oral NAD+ supplement brand for daily cellular vitality support.
  • Niagen® Plus
  • Niagen NanoCloud™

Products and services

  • Tru Niagen Premium food-grade oral NAD+ supplement containing patented nicotinamide riboside (Niagen), clinically proven to boost NAD+ levels by up to 150% and support cellular energy, repair, and healthy aging. Available in various serving sizes via subscription e-commerce at truniagen.com. Targeted at health-conscious adult consumers.
  • Niagen Plus Pharmaceutical-grade NAD+ enhancement therapy delivered through healthcare providers and a new telehealth platform. Includes Niagen IV (intravenous) and injectable formulations available at over 1,200 clinics nationwide plus at-home subcutaneous injection kits dispensed by licensed 503A/503B pharmacies. Targeted at medical patients and clinical operators.
  • Tru Niagen Beauty NAD-focused beauty supplement combining Niagen with astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E to support skin elasticity, hair strength, and nail health from within. Sold via subscription through truniagen.com. Targeted at premium beauty and longevity consumers.
  • Niagen NanoCloud Waterless topical skincare product in sachet format delivering patented Niagen nicotinamide riboside. Protects NR from degradation until point of use, solving instability challenges common in NAD+ skincare formulations. Dermatologist-tested. Targeted at premium anti-aging skincare consumers.
  • Niagen (Nicotinamide Riboside Chloride) Ingredient B2B patented nicotinamide riboside chloride (NRCl) ingredient licensed to manufacturers, healthcare innovators, and brand partners for incorporation into consumer health, nutraceutical, and pharmaceutical products. FDA NDI notified (2015, 2018), GRAS status (2016), USP monograph published. Targeted at consumer health manufacturers and brand partners globally.

Quantifiable outcome

  • Increases NAD+ levels by up to 150%
  • +4 more outcomes

Companies that use Niagen Bioscience

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Niagen Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Niagen Bioscience partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered strategic, core and minor.

  • Taiki (Korean manufacturer)strategicOEM/ Whitelabel/ Licensing Partner · 4 May 2026Partnership with Taiki, a leading Korean manufacturer specializing in innovative delivery formats, for production of Niagen NanoCloud sachets. Waterless powder format developed in partnership protects Niagen until the moment of use, solving stability challenge that limits traditional NAD+ skincare products.
  • Olympia PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 28 April 2026Partnership with Olympia Pharmaceuticals, a U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen for Niagen Plus intravenous and injectable products. Addition diversifies Niagen Bioscience's 503B compounding network beyond existing partner Wells Pharma of Houston, expanding supply chain capabilities to support growth across clinic footprint nationwide. Collaboration meets growing demand for Niagen IV and injections in healthy aging and longevity market.
  • OneSpaWorld HoldingscoreChannel Partner/ Reseller/ Distributor · 31 March 2026Partnership to offer pharmaceutical-grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships, marking the company's first cruise ship clinic partnership. Collaboration extends Niagen's clinical network to new premium distribution point targeting on-vacation consumers seeking wellness experiences, with deployment aligned to ship-specific operations and regulatory requirements. Rollout expected to meaningfully expand OneSpaWorld's fleet footprint while providing scalable pathway for Niagen Plus to reach new consumers.
  • LGC (VHG Labs/LGC Standards)minorOthers · 24 February 2026Sale of ChromaDex Reference Standards business to LGC in all-cash transaction. Deal enables Niagen Bioscience to exit non-core activities and focus on NAD+ science. LGC Standards, a division of LGC Group, acquired analytical reference standards and services business to expand North American commercial reach and enhance reference materials portfolio for pharmaceutical, laboratory, and food production customers.
  • LGC LimitedminorOthers · 24 February 2026LGC Limited acquired ChromaDex Reference Standards from Niagen Bioscience in February 2026, strengthening LGC's ability to serve pharmaceutical customers, testing laboratories, and food producers while expanding North American commercial reach.
  • University of CopenhagenstrategicStrategic or Co-development Partner · 9 February 2026Premiere sponsor of inaugural 'NAD for Health: Opportunities & Challenges' scientific conference hosted by University of Copenhagen (March 23-25, 2026). Conference focuses on NAD metabolism research, aging biology, and translational frameworks, bringing together researchers, clinicians, and industry partners. Dr. Jonas Treebak and Dr. Vilhelm Bohr organizing the event, with Dr. Bohr serving on Niagen Bioscience's Scientific Advisory Board.
  • TruemedstrategicChannel Partner/ Reseller/ Distributor · 29 January 2026Partnership enabling qualified customers to purchase Tru Niagen using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds. Truemed provides a Letter of Medical Necessity for eligible buyers, expanding accessibility of the NAD+ supplement to consumers with pre-tax healthcare accounts.
  • Queen's University BelfastcoreTechnology or Integration · 22 December 2025Acquisition of comprehensive patent portfolio covering nicotinamide riboside (NR) from Queen's University Belfast. Transaction consolidates Niagen Bioscience's leadership position in NAD+ precursor intellectual property, covering manufacturing, composition, and use rights globally. Grant includes various NR salt forms and derivatives, making company sole owner of critical IP in NAD+ industry.
  • Mayo ClinicstrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from Mayo Clinic among 300+ global research collaborations supporting NAD+ science. Mayo Clinic researchers participate in investigator-initiated studies using Niagen materials provided through Material Transfer Agreements.
  • National Institutes of Health (NIH)strategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from National Institutes of Health among 300+ global research agreements. NIH researchers participate in investigator-initiated and third-party funded studies advancing NAD+ biology understanding.
  • Harvard UniversitystrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from Harvard University. Harvard researchers contribute to peer-reviewed publications on NR and NAD+ biology through investigator-initiated studies.
  • Cambridge UniversitystrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from Cambridge University among leading research institutions supporting NAD+ science and clinical studies.
  • MITstrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from MIT contributing to NAD+ precursor research and clinical studies.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Niagen Bioscience competitors and assessment

Company assessment

Direct peers

  • Designs for Health: Designs for Health is a practitioner-grade supplement company with a clinical channel model very similar to Niagen's 1,200+ clinic distribution network. Comparable on professional channel distribution, premium quality positioning, and cellular health product focus.
  • Momentous: Momentous is a premium longevity and human performance supplement brand with scientific advisory ties (e.g., Dr. Andrew Huberman) and an emphasis on cellular health, mitochondrial function, and NAD+ support — a peer in the premium longevity DTC category.
  • Elysium Health: Elysium Health sells Basis, a direct NAD+ precursor supplement combining nicotinamide riboside with pterostilbene, targeting the same cellular aging and longevity use cases as Tru Niagen. It is the most direct head-to-head competitor in the consumer NAD+ category.
  • Pure Encapsulations: Pure Encapsulations is a practitioner-channel premium supplement brand owned by Nestlé Health Science. It serves healthcare practitioners with hypoallergenic, science-backed formulations — comparable to Niagen's clinical channel strategy and quality positioning.
  • Life Extension: Life Extension is a long-established direct-to-consumer longevity supplement brand with a broad catalog including NAD+ and cellular health products. It targets the same health-conscious, anti-aging consumer demographic and competes directly on subscription DTC channels.
  • Thorne HealthTech: Thorne is a premium, practitioner-grade supplement brand with a strong scientific positioning, NSF Certified for Sport, and a similar longevity/cellular health focus. Comparable on premium positioning, clinical channel distribution, and science-led brand-building to Niagen's Tru Niagen line.

Emerging players

  • Neurohacker Collective: Neurohacker Collective sells Qualia line supplements targeting longevity, cognition, and cellular health. It overlaps on longevity positioning and the science-led premium supplement category, though its core focus is broader nootropic/longevity rather than NAD+ specifically.
  • Restore Hyper Wellness: Restore Hyper Wellness is a national franchise of wellness clinics offering IV therapies including NAD+ and has conducted research on Niagen IV tolerability. Comparable as a clinical channel partner and competitor for IV-based NAD+ delivery.
  • Codeage: Codeage is a DTC longevity supplement brand with NAD+, NMN, and cellular aging products targeting the same health-conscious consumer. It is a smaller emerging competitor in the direct NAD+ precursor space.
  • Jinfiniti Precision Medicine: Jinfiniti offers NAD+ testing and measurement services for consumers and researchers, addressing the same NAD+ science ecosystem. It is adjacent rather than directly competitive but operates in the same NAD+ biology category and serves overlapping consumer/research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Niagen Bioscience social profiles

Digital presence

Niagen Bioscience compliance and trust

Trust signal

Compliance11 records

Niagen Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Niagen Bioscience leadership team

Management profile

Number of profiles

Profiles24 records

Niagen Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Niagen Bioscience funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Niagen Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Niagen Bioscience

What does Niagen Bioscience do?

Niagen Bioscience develops, manufactures, and commercializes its patented Niagen (nicotinamide riboside chloride) ingredient across consumer dietary supplements (Tru Niagen, Tru Niagen Beauty), pharmaceutical-grade clinical therapies (Niagen Plus IV and injectables), topical skincare (Niagen NanoCloud), and B2B ingredient licensing to manufacturers. The company operates a direct-to-consumer e-commerce platform, a clinician-directed telehealth platform for prescription at-home injection kits, and a network of over 1,200 clinics.

Is Niagen Bioscience a public or private company?

Niagen Bioscience is a public company. It is classified as public and is currently operating.

When was Niagen Bioscience founded?

Niagen Bioscience was founded in 1999. It employs 101 to 250 people.

Where is Niagen Bioscience based?

Niagen Bioscience is headquartered in Los Angeles, United States, in the North America region.

How does Niagen Bioscience make money?

Five revenue lines are on record. Consumer Supplement Sales (Tru Niagen) is the primary driver. The others are clinical/Pharmaceutical Therapy (Niagen Plus), skincare Products (Niagen NanoCloud), B2B Ingredient Licensing and niagen Beauty Supplement (Tru Niagen Beauty).

Who are Niagen Bioscience's main competitors?

Direct peers on record are Designs for Health, Momentous, Elysium Health, Pure Encapsulations, Life Extension and Thorne HealthTech. Emerging players are Neurohacker Collective, Restore Hyper Wellness, Codeage and Jinfiniti Precision Medicine.

Does Niagen Bioscience have an API?

No public API is recorded for Niagen Bioscience.

What industry is Niagen Bioscience in?

Niagen Bioscience's product category is NAD+ Dietary Supplements. Its primary akta.pro industry code is CRADAGAM, Healthy Aging & Cognitive Support Supplements, with a secondary code of HLAAAFAB, Microbiome-Derived Metabolite Therapeutics (postbiotics). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comNiagen Bioscience at 18th Annual Southwest IDEAS Conference: growth betsNiagen Bioscience presented at the Southwest IDEAS Conference, emphasizing its cash-flow-positive, debt-free status and multiple growth paths. The company cited a 30% stock drop after the FDA reversed NMN legality and a failed Parkinson's trial, while highlighting a new salt-form product and a possible Estée Lauder skincare launch.Simply Wall StAnalysts Are More Bearish On Niagen Bioscience, Inc. (NASDAQ:NAGE) Than They Used To BeAnalysts cut Niagen Bioscience's 2027 revenue and EPS estimates, with consensus revenue of $137m and EPS of $0.048, down from $155m and $0.17. The price target fell 12% to $10.67, and revenue growth is forecast to slow to 9.6% annually from a historical 16%.YahooSurf Champion Kelly Slater Reveals What’s Helping Him Age Better at a Young 54 (Exclusive)Kelly Slater, 54, discussed his partnership with Niagen Bioscience, taking the product as his first morning routine. He also described his calisthenics-based fitness and anti-inflammatory nutrition, and noted the Brazilian surfers' dominance in recent years.TradingViewFreedom Broker maintains Niagen Bioscience at Buy, lowers price target to $6 from $8.50Freedom Broker maintained Niagen Bioscience at Buy and lowered its price target to $6 from $8.50, a 29.4% decrease. The target implies an upside of 189.9% from the Nov 6 close of $2.07.TradingViewCanaccord Genuity maintains Niagen Bioscience at Buy, lowers price target to $7 from $9Canaccord Genuity maintained Niagen Bioscience at Buy and lowered its price target to $7 from $9, a 22.2% decrease. The target implies an upside of 232.5% from the Nov 5 close of $2.10.Business Wire BlogNiagen Bioscience, Inc. Reports Third Quarter 2026 Financial ResultsNiagen Bioscience reported Q3 2026 net sales of $27.2 million, including $23.3 million from Tru Niagen, and a net loss of $1.2 million. The company generated $2.6 million in operating cash flow and ended the quarter with $69.5 million in cash. It also launched new products and announced a clinical trial with Mass General Brigham.TradingViewCanaccord Genuity maintains Niagen Bioscience at Buy, lowers price target to $9 from $10Canaccord Genuity maintained Niagen Bioscience at Buy and lowered its price target to $9 from $10, a 10% decrease. The target implies an upside of 286.3% from the Oct 30 close of $2.33.Longevity.TechnologyNiagen expands at-home injection kit with new liquid formatNiagen Bioscience launched its Niagen Plus pre-filled injection vial via a telehealth platform on 22 October. The kit delivers patented nicotinamide riboside (NR) subcutaneously, bypassing the digestive system, with no mixing required. The company cites over 25 years of research but provides no clinical data or pricing.American Banking and Market NewsNiagen Bioscience, Inc. (NASDAQ:NAGE) Stock Rated “Buy” by Wall Street BrokeragesNiagen Bioscience received a consensus "Buy" rating from five analysts, with an average price target of $10.33. The company reported Q2 EPS of $0.01, meeting estimates, and revenue of $29.78 million. Analysts expect 0.10 EPS for the current year.MarketBeatNiagen Bioscience, Inc. (NAGE) - What Are Researchers Saying About This Stock?Niagen Bioscience shares have an average analyst rating of Buy with a 12-month price target of $10.33. The company reported Q2 EPS of $0.01, meeting estimates, with revenue of $29.78 million. Institutional investors own 15.41% of the stock.